Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11508928 | 0.89 | POLB (0.42) | TSHRALDH1A1KDM4ERAD52LMNA | |
| SCHEMBL11339054 | 0.86 | KDM4E (0.46) | TSHRALDH1A1KDM4ERAD52MITF | |
| SCHEMBL3666211 | 0.86 | POLB (0.46) | TSHRALDH1A1KDM4ERAD52MITF | |
| Hydrochloric Acid SCHEMBL9012929 | 0.84 | KDM4E (0.44) | TSHRALDH1A1KDM4ERAD52MITF | |
| SCHEMBL3633711 | 0.81 | ALDH1A1 (0.44) | TSHRALDH1A1KDM4EGAANR4A2 | |
| SCHEMBL3875390 | 0.78 | NPC1 (0.47) | TSHRALDH1A1RAD52POLBRAB9A | |
| SCHEMBL4034901 | 0.78 | KDM4E (0.40) | TSHRALDH1A1KDM4ERAD52MITF | |
| SCHEMBL3035099 | 0.78 | EGFR (0.41) | ALDH1A1KDM4ERAD52MITFLMNA | |
| SCHEMBL2930867 | 0.77 | ALDH1A1 (0.40) | TSHRALDH1A1GAANR4A2CYP3A4 | |
| SCHEMBL3786027 | 0.77 | ALDH1A1 (0.47) | TSHRALDH1A1KDM4EMITFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| CN-101328150-A | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | CN | claimed |
| CN-100413849-C | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | CN | claimed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | claimed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | claimed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | claimed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| CN-100413849-C | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | CN | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | TSHR 834/4885ALDH1A1 668/4885KDM4E 2187/4885 |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | OPRD1, OPRK1, SDHA | TSHR 3674/4885ALDH1A1 198/4885KDM4E 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.